Waziri Allen
Department of Neurosurgery, University of Colorado Health Sciences Center, 12631 E. 17th Avenue, Aurora, CO 80045, USA.
Neurosurg Clin N Am. 2010 Jan;21(1):31-42. doi: 10.1016/j.nec.2009.08.005.
Abnormalities of cellular immunity are commonly seen in patients with glioblastoma (GBM), and the subsequent relative immunosuppression likely contributes to poor tumor-specific responses in affected individuals. Endogenous immune regulation is likely to limit the efficacy of a wide array of immunotherapeutic strategies, therefore mandating consideration in the continued development of novel treatments for GBM. Various tumor-associated factors have been implicated as potential generators of the immunosuppressive effect. This article outlines relevant experimentation exploring the nature of immune defects in patients with GBM, including a critical discussion of tumor-secreted factors, cell-surface proteins, and more recently described populations of immunoregulatory leukocytes that have potential roles in the subversion of cellular immunity.
细胞免疫异常在胶质母细胞瘤（GBM）患者中很常见，随后的相对免疫抑制可能导致受影响个体的肿瘤特异性反应不佳。内源性免疫调节可能会限制多种免疫治疗策略的疗效，因此在GBM新疗法的持续开发中必须加以考虑。各种肿瘤相关因素被认为是免疫抑制作用的潜在产生者。本文概述了探索GBM患者免疫缺陷本质的相关实验，包括对肿瘤分泌因子、细胞表面蛋白以及最近描述的在细胞免疫颠覆中具有潜在作用的免疫调节白细胞群体的批判性讨论。
